Keith W Pratz, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director, Leukemia Programs, University of Pennsylvania/Abramson Cancer Center
Section Chief Leukemia, University of Pennyslvania
Department: Medicine
Contact information
3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia, PA 19104
South Pavilion Room 12-155
Philadelphia, PA 19104
Education:
BS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Permanent linkBS (Molecular Biology)
University of Maryland at College Park, 1998.
MD (Medicine )
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 2002.
Description of Clinical Expertise
Hematologic Malignancies, Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CML, bone Marrow TransplantDescription of Research Expertise
Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, MDS, AML, ALL, CMLSelected Publications
Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9: 533-544, Feb 2025.Alison Carulli, Brendan L. Mangan, Rachel Hartman, Mrs. Lindsey MacDonald, Mr. Christopher J. Catania, Noelle V. Frey, Saar Gill, Elizabeth O Hexner, Mary Ellen Martin, Nasheed M. Hossain, Alison W. Loren, Selina M. Luger, Shannon R. McCurdy, David L Porter, Keith W. Pratz, Jacqueline Smith, Pashna Munshi: Early Mixed Chimerism and Relapse Rates for Acute Myeloid Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy Feb 2025.
Rowe, M., Babushok, D., Carroll, M., Carulli, A., Frey, N., Gill, S., Hexner, E., Hirsh, R., Hossain, N., Lai, C., Loren, A., Luger, S., Maillard, I., McCurdy, S., Matthews, A., Martin, M.E., Paralkar, V.R., Perl, A., Porter, D., Pratz, K., Stadtmauer, E. and Bruno, X.J. : Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 2025.
Pratz KW, Erba HP.: Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted Agents. Am J Hematol 2025.
Pratz KW.: Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1. Br J Haematol Dec 2024.
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C: The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol November 2024.
Connor MP, Prathapa N, Frey NV, Gill SI, Hexner EO, Bruno XJ, Lai CE, Loren AW, Luger SM, Matthews AH, McCurdy SR, Perl AE, Porter DL, Zeringue A, Oved JH, Olson TS, Pratz KW, Babushok DV: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica 109(8): 2732-2737, Aug 2024.
12. Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D: Ven the dose matters: Venetoclax dosing in the frontline treatment of AML. Blood Rev Aug 2024.
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA: Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood Aug 2024.
Hamilton KW, Hua E, Dutcher L, Fernandez Lynch H, Junker P, Doucette AG, Werner D, Kannel EZ, Civitello T, Gabriel P, Ahya VN, Jacobs DA, Garfall A, Pratz K, Degnan KO, Blumberg EA, Capozzi D, Craig E, Takach P, Payne AS, Geara A, Koenig H, Holzman L, Tebas P: Implementation of an Approach to Equitable Allocation of SARS-CoV-2 Monoclonal Antibodies for Preexposure Prophylaxis: Experience From a Single Medical Center. Open Forum Infect Dis. 11(8), Jul 2024.